UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 11, 2009
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 001-33221 | | 94-2875566 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | |
123 Saginaw Drive Redwood City, CA 94063 | |
| (Address of principal executive offices) | |
(650) 366-2626
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 1.01 | Entry into Material Definitive Agreement |
On September 15, 2009 A.P. Pharma, Inc. (the “Company”) issued a press release announcing that on September 11, 2009, it had entered into a Development and License Agreement (the “License Agreement”) with Merial Limited, a company limited by shares registered in England and Wales (“Merial”), effective as of September 4, 2009 (the “Commencement Date”). Under the License Agreement, the Company has granted to Merial a worldwide, exclusive license to a long-acting pain management product containing an undisclosed analgesic, for use in treating companion animals (cats and dogs). Pursuant to terms of the License Agreement, the Company will receive an upfront payment, certain development funding and potential future milestone payments and certain royalties following commercialization of a licensed product. The term of the license under the License Agreement will continue until the date of expiration of the last patent covered by the license.
Pursuant to the terms of the License Agreement, Merial may terminate the License Agreement for any reason with 90 days’ prior written notice to the Company, and once a license product has been commercially sold, Merial may terminate the License Agreement for any reason with six months’ prior written notice to the Company; provided, however, that Merial is prohibited from terminating the License Agreement within the first six months of the Commencement Date. In addition, Merial may terminate the License Agreement immediately in the event the Company materially breaches certain of its obligations under the License Agreement and such breach remains uncured for a period of 60 days after receipt of notice from Merial, or if the Company becomes insolvent.
The Company may terminate the License Agreement (i) upon 60 days’ prior written notice to Merial if Merial has not filed an administrative New Animal Drug Application (“NADA”) with the U.S. Food and Drug Administration (“FDA”) for a licensed product within a certain period after the Commencement Date or has not commercialized a licensed product within a certain period after receiving approval of the administrative NADA and assignment of a NADA number from the FDA, (ii) if Merial materially breaches certain of its obligations under the License Agreement and such breach remains uncured for a period of 60 days after receipt of notice from the Company or (iii) if Merial becomes insolvent.
In the event of a change of control of a party, the other party may terminate the License Agreement within three months after receiving a notice of change of control by giving at least 12 months’ written notice to the other party.
Upon termination of the License Agreement, among other things, Merial must pay to the Company all royalties and license fees due and owing up to the termination date. In addition, if a licensed product has been launched by Merial prior to termination for any reason except for termination for cause by Merial and Merial seeks to license its rights in the licensed product to another party, the Company is entitled to a first right of negotiation to acquire such license.
The foregoing description of the License Agreement is qualified in its entirety by reference to the full License Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2009. The Company intends to submit a FOIA Confidential Treatment Request to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, requesting that it be permitted to redact certain portions of the License Agreement. The omitted material will be included in the request for confidential treatment.
A copy of the press release dated September 15, 2009 is attached hereto as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
99.1 Press Release of A.P. Pharma, Inc. dated September 15, 2009
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | | A.P. Pharma, Inc. |
| | |
| Date: September 18, 2009 | | |
| | | Ronald J. Prentki |
| | | President, Chief Executive Officer and Director |
